Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

Promoter hypermethylation of the tumor-suppressor genes ITIH5, DKK3, and RASSF1A as novel biomarkers for blood-based breast cancer screening.

Kloten V, Becker B, Winner K, Schrauder MG, Fasching PA, Anzeneder T, Veeck J, Hartmann A, Knüchel R, Dahl E.

Breast Cancer Res. 2013 Jan 15;15(1):R4. doi: 10.1186/bcr3375.

2.

Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours.

Veeck J, Bektas N, Hartmann A, Kristiansen G, Heindrichs U, Knüchel R, Dahl E.

Breast Cancer Res. 2008;10(5):R82. doi: 10.1186/bcr2151. Epub 2008 Sep 30.

3.

Silencing of tumor suppressor genes RASSF1A, SLIT2, and WIF1 by promoter hypermethylation in hereditary breast cancer.

Alvarez C, Tapia T, Cornejo V, Fernandez W, Muñoz A, Camus M, Alvarez M, Devoto L, Carvallo P.

Mol Carcinog. 2013 Jun;52(6):475-87. doi: 10.1002/mc.21881. Epub 2012 Feb 7.

PMID:
22315090
4.

Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients.

Dulaimi E, Hillinck J, Ibanez de Caceres I, Al-Saleem T, Cairns P.

Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6189-93.

5.

Low expression of ITIH5 in adenocarcinoma of the lung is associated with unfavorable patients' outcome.

Dötsch MM, Kloten V, Schlensog M, Heide T, Braunschweig T, Veeck J, Petersen I, Knüchel R, Dahl E.

Epigenetics. 2015;10(10):903-12. doi: 10.1080/15592294.2015.1078049. Epub 2015 Aug 7.

6.

Prognostic relevance of Wnt-inhibitory factor-1 (WIF1) and Dickkopf-3 (DKK3) promoter methylation in human breast cancer.

Veeck J, Wild PJ, Fuchs T, Schüffler PJ, Hartmann A, Knüchel R, Dahl E.

BMC Cancer. 2009 Jul 1;9:217. doi: 10.1186/1471-2407-9-217.

7.

[Novel prognostic marker in invasive breast cancer. ITIH5 expression is abrogated by aberrant promoter methylation].

Veeck J, Breuer E, Rose M, Chorovicer M, Naami A, Bektas N, Alkaya S, von Serényi S, Horn F, Hartmann A, Knüchel R, Dahl E.

Pathologe. 2008 Nov;29 Suppl 2:338-46. doi: 10.1007/s00292-008-1044-9. German.

PMID:
18810445
8.

Epigenetic inactivation of the novel candidate tumor suppressor gene ITIH5 in colon cancer predicts unfavorable overall survival in the CpG island methylator phenotype.

Kloten V, Rose M, Kaspar S, von Stillfried S, Knüchel R, Dahl E.

Epigenetics. 2014 Sep;9(9):1290-301. doi: 10.4161/epi.32089. Epub 2014 Aug 4.

9.

The extracellular matrix protein ITIH5 is a novel prognostic marker in invasive node-negative breast cancer and its aberrant expression is caused by promoter hypermethylation.

Veeck J, Chorovicer M, Naami A, Breuer E, Zafrakas M, Bektas N, Dürst M, Kristiansen G, Wild PJ, Hartmann A, Knuechel R, Dahl E.

Oncogene. 2008 Jan 31;27(6):865-76. Epub 2007 Jul 23.

PMID:
17653090
10.

Epigenetic alterations by methylation of RASSF1A and DAPK1 promoter sequences in mammary carcinoma detected in extracellular tumor DNA.

Ahmed IA, Pusch CM, Hamed T, Rashad H, Idris A, El-Fadle AA, Blin N.

Cancer Genet Cytogenet. 2010 Jun;199(2):96-100. doi: 10.1016/j.cancergencyto.2010.02.007.

PMID:
20471512
11.

Detection of aberrant methylation of a six-gene panel in serum DNA for diagnosis of breast cancer.

Shan M, Yin H, Li J, Li X, Wang D, Su Y, Niu M, Zhong Z, Wang J, Zhang X, Kang W, Pang D.

Oncotarget. 2016 Apr 5;7(14):18485-94. doi: 10.18632/oncotarget.7608.

12.

Detection and monitoring of hypermethylated RASSF1A in serum from patients with metastatic breast cancer.

Kristiansen S, Nielsen D, Sölétormos G.

Clin Epigenetics. 2016 Apr 1;8:35. doi: 10.1186/s13148-016-0199-0. eCollection 2016.

13.

Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer.

Veeck J, Noetzel E, Bektas N, Jost E, Hartmann A, Knüchel R, Dahl E.

Mol Cancer. 2008 Nov 6;7:83. doi: 10.1186/1476-4598-7-83.

14.

Promoter hypermethylation of the tumor-suppressor genes RASSF1A, GSTP1 and CDH1 in endometrial cancer.

Fiolka R, Zubor P, Janusicova V, Visnovsky J, Mendelova A, Kajo K, Lasabova Z, Plank L, Danko J.

Oncol Rep. 2013 Dec;30(6):2878-86. doi: 10.3892/or.2013.2752. Epub 2013 Sep 25.

PMID:
24068440
16.

DNA methylation in pre-diagnostic serum samples of breast cancer cases: results of a nested case-control study.

Brooks JD, Cairns P, Shore RE, Klein CB, Wirgin I, Afanasyeva Y, Zeleniuch-Jacquotte A.

Cancer Epidemiol. 2010 Dec;34(6):717-23. doi: 10.1016/j.canep.2010.05.006.

17.

Circulating cell-free DNA-based epigenetic assay can detect early breast cancer.

Uehiro N, Sato F, Pu F, Tanaka S, Kawashima M, Kawaguchi K, Sugimoto M, Saji S, Toi M.

Breast Cancer Res. 2016 Dec 19;18(1):129.

18.

High RASSF1A promoter methylation levels are predictive of poor prognosis in fine-needle aspirate washings of breast cancer lesions.

Martins AT, Monteiro P, Ramalho-Carvalho J, Costa VL, Dinis-Ribeiro M, Leal C, Henrique R, Jerónimo C.

Breast Cancer Res Treat. 2011 Aug;129(1):1-9. doi: 10.1007/s10549-010-1160-0. Epub 2010 Sep 15.

PMID:
20842524
19.

RASSF1A and CDH1 hypermethylation as potential epimarkers in breast cancer.

Sebova K, Zmetakova I, Bella V, Kajo K, Stankovicova I, Kajabova V, Krivulcik T, Lasabova Z, Tomka M, Galbavy S, Fridrichova I.

Cancer Biomark. 2011-2012;10(1):13-26. doi: 10.3233/CBM-2012-0230.

PMID:
22297548
20.

Validation of DNA promoter hypermethylation biomarkers in breast cancer--a short report.

de Groot JS, Pan X, Meeldijk J, van der Wall E, van Diest PJ, Moelans CB.

Cell Oncol (Dordr). 2014 Aug;37(4):297-303. doi: 10.1007/s13402-014-0189-1. Epub 2014 Aug 16.

PMID:
25123395

Supplemental Content

Support Center